Wegovy injection is approved for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. This is narrower than any fatty-liver diagnosis, and approval relies on biopsy improvements while longer-term outcomes are studied.
What improved in ESSENCE
In the 72-week ESSENCE interim analysis, MASH resolved without worsening fibrosis in 62.9% of semaglutide participants versus 34.3% with placebo. Fibrosis improved without worsening MASH in 36.8% versus 22.4%. These are two separate biopsy-based outcomes; a participant need not meet both to be counted in either result.[1]
The percentages answer a more precise question than whether semaglutide is “good for the liver.” They concern tissue changes in a defined disease population. A lower weight or a better liver blood test is not the same endpoint, even when all three changes occur together.
| At 72 weeks | Semaglutide | Placebo |
|---|---|---|
| MASH resolution without worsening fibrosis | 62.9% | 34.3% |
| Fibrosis improvement without worsening MASH | 36.8% | 22.4% |
The first gap is 28.6 percentage points and the second is 14.4 points, calculated from the reported rounded percentages. Neither means that 62.9% of all people with fatty liver will have a lasting cure. The denominator is the study population, and the measurement is at a specific follow-up.
Fatty liver, MASH and fibrosis are different descriptions
Fatty liver describes fat accumulation. MASH adds inflammation and liver-cell injury; fibrosis describes scarring. The words often get compressed into one search query, yet they change the treatment discussion. A report mentioning fat does not itself establish the disease stage covered by this indication.
FDA describes the approved population as adults with moderate-to-advanced fibrosis. The prescribing information specifies noncirrhotic disease consistent with F2–F3 fibrosis. A person with cirrhosis or an uncharacterized incidental finding is not simply another version of the trial participant.[2] [3]
The useful next document is therefore the assessment explaining the diagnosis and stage. It may be held by a primary-care practice or liver specialist rather than the weight-management service. Keeping that assessment available helps prevent a comparison based only on which website advertises semaglutide.
Accelerated approval leaves an important question open
FDA used accelerated approval and says the trial continues to evaluate whether the earlier tissue improvements translate into fewer deaths, transplants and other liver-related events. That distinction is the central limitation of the current evidence.[2]
A surrogate endpoint can support an important treatment decision without settling every outcome that matters over decades. The evidence should neither be dismissed as “only a biopsy” nor inflated into a proven reduction in liver transplantation. Those are different claims with different data requirements.
The trial comparison also includes background care. It is not evidence that managing other conditions becomes unnecessary once a prescription starts. A treatment plan can contain several useful parts, and the new medicine does not erase the work already being done on metabolic health or liver monitoring.
How this changes the provider comparison
For someone already evaluated for MASH, the service question is coordination: will the prescriber use the specialist’s records, communicate changes and explain which follow-up belongs with each practice? A low monthly headline is less informative if the service cannot manage the reason the medicine is being prescribed.
Our Form Health review examines a care-focused model, while the PlushCare review separates primary-care visits from membership and medication charges. These are service comparisons, not a statement that either can accept every liver-disease patient.
For insurance, identify the exact product and documented indication before requesting the plan’s criteria. An obesity exclusion and a MASH claim may raise different questions; neither a diagnosis nor FDA approval guarantees payment. The prior-authorization guide explains the distinction between a benefit and permission to use it.
Record specialist visits, medication, laboratory charges and telehealth membership separately in the first-year cost comparison. The relevant price is the cost of the care arrangement that can actually support the condition, not the cheapest unrelated ingredient offer.